Definium Therapeutics Goodwill

Definium Therapeutics (DFTX) currently reports a goodwill of $20M as of June 2026. That compares with $20M in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Definium Therapeutics's goodwill history and peer comparisons.

Definium Therapeutics's goodwill was unchanged from $20M to $20M — essentially flat versus a year earlier (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Definium Therapeutics reported $20M in goodwill as of June 2026. That compares with $20M in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current goodwill of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Definium Therapeutics, and consider following DFTX for alerts when major investors trade the stock.

Definium Therapeutics is classified in the Healthcare sector. On goodwill, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DFTX with unrelated industries.